Drug Approval | October 04, 2021
Lilly to transfer rights of two diabetes drugs to Cipla in India
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
Fastminar is a 40-feet structure made with approximately 80,000 toothbrushes and is located at Terna Dental College in Navi Mumbai
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
Subscribe To Our Newsletter & Stay Updated
